The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy by de Almagro, M.C. & Vucic, D.
200 Experimental Oncology 34, 200–211, 2012 (September)
THE INHIBITOR OF APOPTOSIS (IAP) PROTEINS ARE CRITICAL 
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Cell death regulation is vital for maintenance of homeostasis and proper development of multicellular organisms. Inhibitor of apop-
tosis (IAP) proteins are implicated in multiple ways in cell death regulation, ranging from inhibition of apoptosis and necrosis to the 
regulation of cell cycle and inflammation. Due to their prominent ability to control cell death and elevated expression in a variety 
of cancer cell types, IAP proteins are attractive targets for the development of novel anti-cancer treatments. The most widely 
used strategy for targeting IAP proteins is based on mimicking the natural IAP antagonist, SMAC/DIABLO. IAP antagonists 
are currently being tested in humans and they were designed for anti-cancer therapy but they could potentially also be considered 
for treatments of the immune system disorders. In this manuscript we will review the functional roles of IAP proteins, specifically 
of c-IAP1, c-IAP2, ML-IAP and XIAP, and evaluate IAP targeting strategies for disease treatments. This article is part of a Special 
Issue entitled “Apoptosis: Four Decades Later”.
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The balance between cell death and survival is one 
of the main features of cellular homeostasis [1]. Cell 
death could be seen a priori as something negative 
but programmed mechanisms such as apoptosis 
or necroptosis have important roles in maintenance 
of desired cell number [2]. Apoptosis is critical in em-
bryogenesis, where certain cells need to die in order 
to allow the formation of particular morphological 
features [3]. Programmed cell death is also beneficial 
for prevention of tumors or the spread of infectious 
diseases, as it enables elimination of damaged or in-
fected cells, or cells that harbor too many mutations.
The inhibitors of apoptosis (IAP) proteins are 
a family of proteins that are involved in cell death, 
immunity, inflammation, cell cycle and migration [4]. 
The members of this protein family are characterized 
by the presence of one to three baculoviral IAP repeats 
(BIR) domains [5]. 
IAPs were first identified in 1993 in baculoviral 
genomes because of their ability to suppress the 
host-cell death response during viral infection [6, 7]. 
The first identified human IAP protein, NAIP, as well 
as X-chromosome-linked IAP (XIAP), were identified 
using homology searches for BIR domain containing 
proteins [8]. Cellular IAP proteins (c-IAPs) were first 
identified as components of the Tumor Necrosis Fac-
tor Receptor 2 (TNFR2) complex, which is mediated 
through binding to TRAF1 and TRAF2 [9].
The human IAP family is composed of eight pro-
teins: NAIP (BIRC1), c-IAP1 (BIRC2), c-IAP2 (BIRC3), 
XIAP (BIRC4), survivin (BIRC5), Apollon/Bruce 
(BIRC6), ML-IAP (BIRC7 or livin) and ILP-2 (BIRC8). 
Among these IAP proteins, c-IAP1, c-IAP2, ML-IAP 
and XIAP are directly involved in apoptosis regulation 
[10], while other members of the family can regulate 
cell survival by other means such as cell cycle control 
or inflammation. In this review we focus on c-IAP1, 
c-IAP2, XIAP and ML-IAP, and their role in cell death 
and signaling pathways with emphasis on potential 
new anti-cancer treatments.
IAP PROTEINS AND APOPTOTIC 
PATHWAYS
Apoptosis is a meticulously regulated cell death 
program that relies on caspases, a family of cysteine-
dependent aspartic acid proteases [11]. Caspases 
are synthesized as inactive proteins or zymogens, but 
once they dimerize or are cleaved by another protease, 
usually another caspase in the caspase activation 
cascade, they become active enzymes [11]. Although 
caspases are well known because of their role in apop-
tosis, some caspases are involved in cytokine process-
ing, such as IL-1β processing by caspase-1. Apoptotic 
pathways engage 2 types of caspases, the initiator 
(caspase-2, -8 and -9) and the effector caspases 
(caspase-3, -6 and -7) [12]. 
Apoptosis can be activated via an extrinsic 
or death-receptor-mediated pathway and an intrinsic 
or mitochondrial pathway (Fig. 1). The extrinsic apop-
totic pathway is initiated by activation of death recep-
tors of the TNF receptor superfamily by their respective 
ligands. This superfamily is composed of transmem-
brane proteins that share a conserved extracellular 
cysteine-rich domain. The death receptor members 
of the TNFR superfamily possess intracellular death 
domains (DD) and include: TNFR1, Fas (CD95, 
APO-1), and death receptors 3, 4 and 5 (DR3, DR4 and 
DR5) [13, 14]. The activation of these receptors leads 
to the formation of a receptor-associated complex 
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of Fas-associated DD (FADD) and caspase-8 and 
-10 that triggers caspase-8/-10 activation, and subse-
quent cleavage of caspase-3 and -7 for apoptosis ini-
tiation [15]. For TNFR1, the cytokine TNFα binds to the 
receptor and triggers its trimerization, which leads 
to the assembly of the receptor complex and initiation 
of signaling. The death domain of TNFR1 recruits TNF 
receptor associated death domain protein (TRADD), 
an adaptor molecule that allows binding of TRAF2 and 
c-IAP1 and c-IAP2 to the receptor complex [16]. The 
DD containing kinase RIP1 can bind TNFR1 through 
TRADD association, although the binding of RIP1 to the 
TNFR1 has also been observed in TRADD deficient 
cells [17, 18].
c-IAP1 and c-IAP2 regulate the extrinsic apoptotic 
pathway through their ubiquitin ligase activity [19]. 
c-IAP proteins are responsible for RIP1 ubiquitination, 
and in their absence RIP1 cannot be ubiquitinated [20, 
21]. Nonubiquitinated RIP1 can form a cytosolic com-
plex with the adaptor molecule FADD and caspases-8, 
leading to induction of apoptosis [20, 22]. In addition 
to c-IAP proteins, another major negative regulator 
of death-receptor-mediated cell death is cellular FLICE 
inhibitory protein long (FLIPL), a protein similar to cas-
pases-8 but with no catalytic activity [23].
The intrinsic pathway is initiated by cellular stress, 
growth serum withdrawal, DNA damage, radiation 
or other stress signals that are detected by Bcl-
2-homology 3 only (BH3-only) proteins resulting 
in alterations of the outer mitochondrial membrane 
potential and permeability (see Fig. 1) [24]. This 
will cause the release of cytochrome c and second 
mitochondria-derived activator of caspase (SMAC)/ 
direct IAP binding protein with low pI (DIABLO) from the 
mitochondria. Cytochrome c released to the cytosol 
binds apoptosis protease activating factor (Apaf1) and 
induces formation of the apoptosome, which leads 
to the activation of caspase-9 and later caspase-3 and 
-7. XIAP inhibits caspase-3, -7 and -9 directly by bind-
ing to them. Meanwhile, SMAC can bind XIAP through 
its N-terminal IAP-binding motif (IBM), AVPI, prevent 
its inhibition of caspase-3, -7 and -9, and thus remove 
the apoptosis blockade [10].
Apart from SMAC, there are additional factors that 
can inhibit XIAP in order to allow apoptosis. Another 
mitochondrial protein that inhibits XIAP is Omi/HtrA2. 
Similarly to SMAC, this serine protease has an IAP-
binding motif with the sequence AVPS [25]. Omi/
HtrA2 has a dual pro-apoptotic activity: on one hand 
it blocks XIAP binding to caspases, and on the other its 
protease activity cleaves XIAP rendering it unfunctional 
[25]. XIAP-associated factor 1 (XAF1) can also bind 
XIAP, c-IAP1/2 and other IAP proteins and interfere 
with their anti-apoptotic activity [26, 27].
Among the numerous proteins and protein com-
plexes that control apoptotic pathways, IAP proteins 
play an important role. There are two predominant 
ways by which IAP proteins regulate apoptosis. c-IAP 
proteins do not bind caspases at a physiologically 
meaningful level [28]. Instead, they regulate caspase 
activation indirectly through their E3 ligase activity and 
modulation of TNF-mediated cell death as well as Toll 
signaling, innate immunity and NF-κB pathways [19, 
29–31]. Anti-apoptotic activity of XIAP stems primarily 
from its direct binding to and inhibition of caspase-3, 
-7 and -9 [32, 33].
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Fig. 1. The intrinsic and extrinsic apoptotic pathways
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IAPS STRUCTURE AND FUNCTION
All IAP proteins contain at least one BIR domain, 
and several also possess a Ubiquitin Associated 
domain (UBA) domain and a Really Interesting New 
Gene (RING) domain (Fig. 2) [33]. c-IAP1, c-IAP2, 
NAIP and XIAP each contain three BIR domains, while 
ML-IAP, survivin, Bruce and hILP2 contain only one. 
Baculovirus IAP Repeats are zinc-binding domains 
of approximately 80 amino acids [5] that mediate 
protein–protein interactions and, in some cases, the 
binding and inhibition of caspases [34, 35]. The BIR 
domains coordinate a zinc ion through one histidine 
and three cysteine amino acid residues [36]. The N-
terminal BIR domain (BIR1) of c-IAP1, c-IAP2 and XIAP 
is well conserved across species. However, even small 
sequence diversity allows binding to different binding 
partners: XIAP BIR1 binds TAB1 [37], while c-IAP1 and 
c-IAP2 BIR1 domains are necessary and sufficient 
for binding TRAF2 [38, 39]. The subtle differences 
in the N-terminal regions of the BIR1 domains provide 
c-IAP1 and c-IAP2 with the unique ability within the 
IAP family to interact with TRAF1 and TRAF2 [38–40].
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Fig. 2. Schematic representation of human IAP proteins
XIAP binds caspases through its BIR2 or BIR3 do-
mains. The XIAP BIR2 domain and the linker region be-
tween the BIR1 and BIR2 domains are needed for the 
inhibition of activated caspas-3 and -7 [41–43]. This 
linker region of XIAP blocks the active site of those cas-
pases, and XIAP BIR2 makes important contacts with 
the N-terminal regions of the small subunits of par-
tially processed caspase-3 and -7 [41, 44]. The XIAP 
BIR3 domain targets and inhibits caspase-9 by binding 
caspase-9 monomer and preventing its dimerization 
and activation [45, 46]. Smac preferentially binds the 
BIR3 domain of c-IAPs and XIAP, although Smac can 
also associate with the BIR2 of XIAP [38, 47]. Smac, 
an endogenous IAP antagonist, is a dimer in solution, 
and it can bind the BIR2 and BIR3 domains of XIAP 
simultaneously to prevent XIAP from binding and in-
hibiting caspase-3, -7 and -9 [48, 49].
Apart from the BIR domains, another common 
feature among c-IAP1, c-IAP2, ML-IAP, hILP2 and 
XIAP is the possession of a C-terminal RING domain 
that provides these proteins with E3 ubiquitin ligase 
activity [50]. RING dimerization strongly potentiates 
the ubiquitin ligase activity [51]. IAP proteins have been 
shown to homodimerize and heterodimerize, thus 
allowing autoubiquitination and trans-ubiquitination 
within the family [52]. In addition, IAP proteins can 
promote ubiquitination of a number of their binding 
partners and other proteins that are present in the 
same signaling complexes. The most important feature 
of this 40 amino acid zinc-coordinating domain is the 
recruitment of E2 ubiquitin conjugating enzymes [50]. 
The RING domains of IAP proteins show a preference 
for the UbcH5 family of E2 enzymes although individual 
IAPs also have unique E2 partners [53]. The XIAP RING 
domain can mediate K48-linked polyubiquitination and 
affect the levels of caspase-3 and itself [54]. Further-
more, mice expressing a RING-deleted XIAP exhibit 
more apoptosis in the presence of TNFα or TRAIL than 
wild type animals [54]. Similarly, Drosophila DIAP1 can 
promote ubiquitination of fly caspases as well and thus 
inhibit apoptosis [55]. 
Another domain common to c-IAP1, c-IAP2, XIAP 
and hILP2 is the ubiquitin-associated (UBA) domain, 
a conserved domain located between the BIR and the 
RING domains [56, 57]. The IAP UBA domain enables 
IAP proteins to bind a variety of ubiquitin chains includ-
ing K63, K48, K11 and linear chains as well as monou-
biquitin [57]. c-IAP1 and c-IAP2 also have a Caspase 
Recruitment Domain (CARD) whose function is not yet 
completely understood.
IAP PROTEINS AND UBIQUITIN
Ubiquitination is one of the main post-translational 
protein modifications found in eukaryotic cells [58]. 
In addition to regulating efficient control of protein deg-
radation and turnover, ubiquitination can modify the 
enzymatic activity of many important cellular regulators 
and alter cellular localization of substrate proteins. 
Ubiquitination involves covalent attachment of the 
76 amino acid protein ubiquitin to a lysine of a target 
protein. This process is carried out by an E1 ubiquitin-
activating enzyme, an E2 ubiquitin conjugating enzyme 
and an E3 ubiquitin ligase, with E3 enzymes providing 
the substrate specificity. There are two E1s, around 
50 E2s, and over 600 E3s [59]. Two types of RING 
E3 ligases can be found: ones that form a multiprotein 
complex with substrate binding protein(s), and oth-
ers where the E2 binding and the substrate binding 
domains are encoded by the same polypeptide [60]. 
IAP proteins belong to the later group as they use 
predominantly their BIR domains for substrate bind-
ing and the RING for the interaction with E2 enzymes 
[50]. Ubiquitinion can result in the transfer of a single 
ubiquitin molecule to target proteins — monoubi-
quitinion, or in the assembly of polyubiquitin chains. 
Since ubiquitin has seven lysines and an N-terminal 
methionine, eight different kinds of ubiquitin chains are 
possible: linear (through N-terminus), K6, K11, K27, 
K29, K33, K48, K63, although the most common and 
best studied are K48 and K63 linkage chains. In most 
cases K48 chains of more than four ubiquitins tag 
a protein for 26S proteasomal degradation [50], while 
K63-linked chains can provide a signal for functional 
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activity or change of cellular distribution. c-IAP pro-
teins are capable of promoting the assembly of a wide 
range of different ubiquitin chains on their substrates 
and on themselves. 
The best-known substrates for the E3 ligase activity 
of c-IAP proteins are RIP1 and NIK. c-IAP1/2 mediated 
polyubiquitinatination of RIP1 is the critical signal need-
ed for the activation of the canonical NF-κB signaling 
pathway [20, 21]. In the noncanonical NF-κB pathway 
c-IAP1 and c-IAP2 promote K48-linked polyubiquiti-
nation of NIK, which blocks noncanonical NF-κB ac-
tivity [31, 47]. Apart from RIP1 and NIK, c-IAP1 and 
c-IAP2 promote ubiquitination of a variety of signal-
ing molecules including TRAF2, TRAF3, Ask, as well 
as Smac, which may have direct implications for cel-
lular survival [19, 50]. XIAP ubiquitination activity does 
not seem to be essential for its anti-apoptotic activity 
but it can still influence caspase stability and cellular 
survival [54].
REGULATION OF SIGNALING PATHWAYS 
BY IAP PROTEINS
NF-kB signaling pathways
The NF-κB family of transcription factors trans-
duces the signal from a variety of stimuli leading to the 
transcription of a broad spectrum of genes involved 
in cell survival, immunity, and inflammation. There 
are five different types of NF-κB transcription factors: 
p50 or NF-κB1 (formed from a selective degradation 
of p105), p52 or NF-κB2 (generated from its p100 pre-
cursors), RELA or p65, RELB and c-REL [61]. Due 
to the high relevance of NF-κB pathways for cellular 
immunity and survival, they are tightly regulated by two 
crucial post-translational modifications, phosphoryla-
tion and ubiquitination. Two NF-κB signaling pathways, 
the canonical and the noncanonical, can be generally 
differentiated by the timing and signaling proteins that 
are involved in their activation (Fig. 3) [62].
Canonical NF-kB
The best-studied stimulus for the initiation of ca-
nonical NF-κB signaling is TNFα. Binding of TNFα 
to TNFR1 triggers the recruitment of the proximal 
receptor-associated complex consisting of TRADD, 
TRAF2, c-IAP1, c-IAP2 and RIP1 [16]. TRAF2 is one 
of seven TRAF proteins present in mammals. All TRAFs 
contain a TRAF domain and, except TRAF1, an N-ter-
minal RING domain — although the RING domain is not 
functional in most of them. c-IAP1 and c-IAP2 bind 
TNF receptors through association with TRAF2. The 
BIR1 domain of c-IAP proteins binds the TRAF-N do-
main of TRAF2, and structural studies revealed that 
one c-IAP protein binds three TRAF2 molecules [40]. 
Ligand-stimulated aggregation of receptor complexes 
causes recruitment of multiple TRAF2 trimers, which 
in turn leads to c-IAP1 or c-IAP2 dimerization, activa-
tion of c-IAP E3 ligase activity and consequent ubiq-
uitination of the kinase RIP1, themselves and other 
binding partners [40, 63].
RIP1 is a critical mediator of several signaling path-
ways because its posttranslational modifications can 
lead to the activation of NF-κB, apoptosis or necrosis. 
In the NF-κB pathway c-IAP1 and c-IAP2 mediate 
K63- and K11-linked polyubiquitination of RIP1 [53]. 
RIP1 ubiquitination allows the binding of the IκB 
kinase, IKK (IKKα/IKKβ/NF-κB essential modifier, 
NEMO) complex, the pro-survival kinase Transform-
ing Growth Factor β-activated Kinase 1, TAK1-TAB 
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Fig. 3. Canonical and noncanonical NF-kB pathways
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(TAK1/ TAK1-binding protein 2,TAB2/ TAK1-binding 
protein 3, TAB3) complex, and LUBAC, a complex con-
taining two regulatory subunits: SHANK-associated 
RH domain interactor (SHARPIN) and heme-oxidized 
IRP2 ubiquitin ligase 1 homolog (HOIL-1L), and the 
catalytic subunit HOIL-1-interacting protein (HOIP)
[64–68]. Interestingly, the kinase activity of RIP1 does 
not seem to be needed for the activation of the ca-
nonical NF-κB pathway [69]. Ubiquitinated RIP1 brings 
LUBAC and NEMO in proximity, which allows subse-
quent linear ubiquitination of NEMO by LUBAC [64, 
65]. But the RIP1 relationship with c-IAP1/2 is not 
limited to NF-κB activation, because in the absence 
of c-IAP1 and c-IAP2 TNFα stimulation can lead 
to RIP1-mediated apoptosis or necroptosis.
NEMO, along with the other subunits of the IKK 
complex, IKKα and IKKβ, is recruited to the RIP1-
assembled polyubiquitin chains in a TRAF2/c-IAP1/
RIP1 dependent manner [70]. The ubiquitination 
of RIP1 brings the IKK complex into proximity of the 
TAK1 kinase complex, leading to phosphorylation and 
activation of IKKβ [71]. IKKβ phosphorylation triggers 
IκBα phosphorylation at two N-terminal serines [72], 
which is a signal for IκBα K48-linked ubiquitination 
by the F-box/WD-domain protein of the β-TrCP/
Slimb family and subsequent proteasomal degrada-
tion [73]. In non-stimulated cells, IκBα sequesters the 
NF-κB transcription factors in the cytoplasm, but the 
degradation of IκBα frees p65 and RelA and enables 
them to translocate to the nucleus. The NF-κB sub-
units can act as homo or heterodimers [74]. Once 
in the nucleus, NF-κB transcription factors bind the 
promoters that harbor NF-κB recognition elements 
and induce their transcription [62]. Therefore, c-IAP 
proteins should be considered as critical positive regu-
lators for the activation the NF-κB canonical pathway.
Noncanonical NF-kB
One of the properties that differentiates the non-
canonical from the canonical NF-κB pathway is the 
timing, since its activation is much slower than the 
canonical pathway due to a requirement for new 
protein synthesis. In addition to activating canonical 
NF-κB signaling, several TNF receptor family mem-
bers, including FN14, LTβR and CD40, can stimulate 
the noncanonical NF-κB pathway. 
In unstimulated cells c-IAP1/2, TRAF2 and 
TRAF3 constitutively associate with NIK, the key 
regulator of noncanonical NF-κB signaling [75, 76]. 
Through association with c-IAPs and NIK, TRAF2 and 
TRAF3, respectively, bring c-IAP proteins in proxim-
ity of NIK. c-IAP1 and c-IAP2 promote ubiquitination 
of NIK with K48 linkages and tag it for proteasomal 
degradation, thus preventing noncanonical NF-κB ac-
tivation [77]. Activation of TNF superfamily receptors 
such as CD40, or the treatment with IAP antagonists, 
causes dimerization of c-IAP proteins, which in turn 
stimulates their autoubiquitination and proteasomal 
degradation [63]. Recruitment of c-IAPs, TRAF2 and 
TRAF3 to CD40 or TWEAK receptor complexes leads 
to their translocation to SDS soluble fractions, autou-
biquitination and ultimately degradation [63, 77]. The 
loss of c-IAP proteins releases NIK from degradative 
ubiquitination, thus allowing its accumulation [47]. NIK 
phosphorylates IKKα dimers, leading to subsequent 
phosphorylation of p100 at its C-terminus, which 
triggers its ubiquitination [78]. Polyubiquitinated 
p100 is subject to partial proteasomal degradation from 
its C-terminus to yield a truncated fragment of p100, 
p52 [78]. The p52 fragment dimerizes with RelB and 
translocates to the nucleus where it binds the pro-
moter regions of NF-κB dependent genes to activate 
their transcription. Therefore, c-IAP1 and c-IAP2 are 
negative regulators of noncanonical NF-κB signaling 
through their ability to suppress cellular NIK levels. 
After the c-IAP proteins are degraded or removed from 
their substrate NIK the noncanonical NF-κB pathway 
can be activated. 
Regulation of other signaling pathways by IAP 
proteins
In addition to NF-κB regulation, IAP proteins play 
important role in other signaling pathways, such as Jun 
N-terminal kinase (JNK), p38 mitogen-activated protein 
kinase (MAPK), TGF-β, Myc, and PI3K/Akt [79–83]. The 
JNK and p38 pathways can be activated by the TNF 
family members leading to transcriptional activation 
of a series of genes through Fos and Jun [84].
The importance of c-IAP1 and c-IAP2 for the ac-
tivation of MAPK signaling was shown in cells stimu-
lated with different TNF ligands: TNFα, TL1A, TWEAK, 
or CD40L. Elimination of c-IAP1 and c-IAP2 resulting 
from IAP antagonist BV6 treatment drastically reduced 
the activation of MAPK p38 and JNK [63]. Further-
more, it was observed in B cells from c-IAP1 and 
c-IAP2 knockout mice that after CD40L stimulation, 
there was no phosphorylation of JNK, ERK or p38 [85]. 
Data from these reports suggest that the ubiquitin 
ligase activity of c-IAP proteins is critical not only 
for NF-κB pathways but also for efficient activation 
of MAPK signaling [63].
IAPS IN INFLAMMATION AND IMMUNITY
In addition to the involvement of IAP proteins 
in apoptosis, there are an increasing number of studies 
that link IAPs to innate immunity and inflammation. One 
of the reasons for this association is the ability of c-IAP 
proteins to regulate the expression of genes involved 
in innate immunity through the NF-κB and MAPK sig-
naling pathways. However, they can also control cell 
death as a result of pathogen infections. 
Innate immunity represents the defense mecha-
nism against external pathogens. Immune cells can 
detect the pattern recognition receptors (PRRs) and 
initiate an immune response. There are different re-
ceptors for pathogen-associated molecular patterns 
(PAMPs): Toll-like receptors (TLRs) at the cellular 
membrane, and nucleotide-binding and oligome-
rization domain (NOD)-like receptors (NLRs) as well 
as DNA and RNA sensing receptors in the cytosol [29].
c-IAP1 and c-IAP2 are implicated in innate immu-
nity because of their ability to ubiquitinate RIP2 and 
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mediate NOD signaling [29]. When NOD receptors are 
activated by bacterial peptidoglycans, they oligome-
rize and recruit c-IAP1/2, TRAF2 and RIP2. This allows 
c-IAP1/2 mediated K63-linked polyubiquitination 
of RIP2, which in turn recruits TAK1-TAB1/2/3 and IKK 
complexes and leads to MAPK and NF-κB activation 
and induction of cytokines and expression of proin-
flammatory genes [29, 86, 87]. 
XIAP has been speculated to have a role in trans-
forming growth factor β (TGF-β) and bone morphoge-
netic protein (BMP) signaling, mainly through its ability 
to bind the kinase complex of TAK1 and TAB1 through 
its BIR1 domain [37, 88], although there was no proof 
that XIAP regulates these pathways in an endogenous 
setting. More recent data suggests that XIAP has 
a potentially instrumental role in immune response 
to intracellular bacteria, as cells lacking XIAP show de-
ficiency in the activation of the NF-κB pathway follow-
ing NOD2 receptor activation [89]. XIAP is proposed 
to exert its role by being the critical ubiquitin E3 ligase 
for RIP2, and the main instigator of LUBAC recruitment 
to the NOD2-associated complex [90]. 
c-IAP1/2 have been reported to promote 
TRAF3 K48-linked ubiquitination, but also nondeg-
radative ubiquitination of TRAF3 and TRAF6, which 
is potentially important for type I IFN induction and 
antiviral response [91]. TRIF-dependent signals trig-
ger K63-linked polyubiquitination of TRAF3 leading 
to IRF3 activation [59]. Knockdown of c-IAP1/2 result-
ed in the inhibition of virus-induced activation of IRF3, 
NF-κB, INF-β and the cytoplasmic dsRNA, retinoic 
acid-inducible gene (RIG-1) antiviral response [91].
IAP proteins can potentially regulate IL-1β produc-
tion as well. IL-1β is a proinflammatory cytokine that 
is activated by caspase-1 cleavage and secreted in re-
sponse to cell damage or pathogens [92]. However, 
in the presence of Smac mimetics, both caspase-1 and 
caspase-8 have been observed to process IL-1β 
in Toll-like receptor primed macrophages [92]. This 
IL-1β production in the absence of IAPs is dependent 
on RIP3, so it is believed that c-IAP1/2 and XIAP prevent 
RIP3 activation, thus inhibiting NLRP3-stimulated IL-1β 
cleavage [92].
XIAP has also been described as a protection 
factor against Sendai virus (SeV) infection [93]. SeV 
infection activates the kinases IKKε and TBK1, which 
can phosphorylate XIAP and trigger its K48-linked 
autoubiquitination and proteasomal degradation [93]. 
XIAP degradation will then allow apoptosis and avoid 
the spread of the virus.
THE ROLE OF C-IAP PROTEINS 
IN REGULATION OF RIP1
The regulation of the serine/threonine kinase 
RIP1 represents an important cellular checkpoint be-
cause the presence and post-translational modifica-
tions of RIP1 can be the determining factor between 
cell death and survival. RIP1 is a founding member 
of a family of kinases that is characterized by the pre-
sence of a kinase domain, an intermediate domain, 
and a death domain that allows RIP1 to interact with 
TRADD and FADD [94]. c-IAP proteins are main regu-
lators of RIP1 through their ubiquitin ligase activity. 
As described before, c-IAP1 and c-IAP2 mediated 
ubiquitination of RIP1 leads to canonical NF-κB path-
way activation. But when c-IAP proteins are absent, 
like in the presence of IAP antagonists, RIP1 cannot 
be ubiquitinated, which precludes the binding of either 
TAB2/3-TAK1 or NEMO. This process can be also 
achieved in the presence of c-IAP1 when RIP1 gets 
deubiquitinated by the deubiquitinases CYLD (cyl-
indromatosis) or A20. Nonubiquitinated RIP1 can 
dissociate from the TNFR1 complex and bind FADD 
and caspase-8 resulting in the initiation of apoptosis. 
Apart from apoptosis, RIP1 can also trigger another 
type of cell death, necroptosis. Necroptosis is a pro-
grammed form of necrosis that relies on RIP1 and RIP3, 
and occurs when apoptosis pathways are blocked 
[95]. Necroptosis drives cell death in a caspase inde-
pendent manner. The initial steps of necroptosis are 
similar to apoptosis, where TNFα binds to TNFR1 and 
the absence of c-IAPs prevents ubiquitination of RIP1. 
But during necroptosis RIP1 does not enter into 
a complex with FADD and caspase-8. In the absence 
of FADD or if caspase activity is inhibited, RIP1 will 
bind the kinase RIP3 leading to a series of auto and 
cross phosphorylation events culminating in the for-
mation of the necrosome and activation of necrosis. 
RIP1 binds RIP3 through their RIP homotypic interac-
tion motif (RHIM) [94]. 
The identity of molecules that mediate the necroptosis 
pathway downstream of RIP3 has remained an unsolved 
mystery for some time. However, a recent discovery 
has revealed mixed lineage kinase domain-like (MLKL) 
as the critical RIP3 target important for necroptosis [96, 
97]. The Wang group proposed that phosphorylated 
RIP3 binds and phosphorylates MLKL [97]. In support 
of its crucial role in necroptosis, knock down of MLKL 
fully rescues cells from necrotic cell death [96]. Another 
RIP3-binding protein that has been described is PGAM5. 
PGAM5 is a phosphatase that provides a mitochondrial 
link to the RIP1–RIP3–MLKL complex and ensures ef-
ficient activation of necrosis [98].
Finally, some viruses, like the murine cytomega-
lovirus, have found a way to block cell necrosis. Cy-
tomegaloviruses encode a RHIM protein domain that 
allows binding to RIP3, thereby blocking its interaction 
with RIP1 and activation of necroptosis [99].
CANCER
Cancer cells have acquired survival capabilities 
that allow them to grow in suboptimal conditions and 
to escape from cell-death signals [100]. Mutations 
in the apoptotic pathways can cause tumor initiation, 
progression or metastasis, since resistance to cell 
death gives cancer cells a survival advantage and 
leads to resistances to anti-tumor treatments [101].
IAP proteins are often overexpressed in cancers, 
which makes them attractive as therapeutic targets 
[102]. In a study of the expression levels of different 
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IAPs across cancer cell lines, XIAP and c-IAP1 were 
expressed in almost all and c-IAP2 in more than half 
of the examined samples [102]. Interestingly, the 
mRNA levels of XIAP, c-IAP1 and c-IAP2 did not cor-
relate with protein levels in the tumor lines, suggesting 
a post-transcriptional regulation [102]. 
The higher expression of IAP proteins might con-
tribute to colon cancer and poor prognosis of colorec-
tal cancer patients [103]. XIAP has been reported 
to be overexpressed in breast cancers, melanomas 
and clear-cell renal carcinoma [104, 105]. In contrast, 
in non-small cell lung cancer patients, XIAP potentially 
correlated with a good prognosis [106], and high levels 
of XIAP were observed to correlate with high sensitivity 
to the chemotherapeutic cytarabine as well as other 
nucleoside analogs [102]. c-IAP proteins have been 
implicated in resistance to treatment of cervical tu-
mors and other types of cancer [102, 107]. In multiple 
myeloma patients that undergo drug resistance, the 
overexpression of survivin, c-IAP1, c-IAP2, and XIAP 
was associated with a poor prognosis [108]. In mu-
cosa-associated lymphoid tissue (MALT) lymphoma, 
the most common subtype of lymphomas, a gene 
translocation gives rise to a fusion protein between 
c-IAP2 and the paracaspase MALT1 [109]. The fusion 
takes place between the BIR domains of c-IAP2 and 
various C-terminal portions of MALT1 [109]. This fusion 
protein has pro-oncogenic properties as it can con-
stitutively activate the NF-κB pathway independently 
of the adaptors (TRAFs) and cleave its substrates in the 
absence of extracellular stimuli [39, 110].
ML-IAP, as its name indicates, is highly overex-
pressed in melanomas, but very rarely in other tissues 
[111]. In melanomas and in non-small cell lung cancer, 
ML-IAP overexpression has been observed to confer 
resistance to apoptosis [112]. ML-IAP overexpression 
in tumors has been related to poor prognosis [113]. 
In melanomas, ML-IAP expression has been linked 
to the pro-survival oncogene Microphthalmia-Associ-
ated Transcription Factor (MITF) [114]. Survivin is also 
almost exclusively expressed in tumor cells at higher 
levels [115]. In colorectal cancer, overexpression 
of survivin in the cytoplasm was associated with poor 
patient prognosis [116]. 
IAPs are involved in cancer due to their ability 
to inhibit apoptosis but also because they mediate 
pro-survival signals due to the activation of NF-κB and 
MAPK signaling pathways, contributing to tumor cell 
proliferation. Together with strong expression in can-
cer tissue, these properties suggest that IAP proteins 
are attractive targets for anti-tumor therapy.
TARGETING IAP PROTEINS
The two main strategies for targeting IAP proteins 
involve Smac-derived peptides and small-molecule 
antagonists, and antisense oligonucleotides [117]. The 
small-molecule IAP antagonists can be further divided 
into monovalent and bivalent IAP antagonists [118]. 
The monovalent antagonists emulate one Smac AVPI 
motif, while the bivalent antagonists comprise two AVPI 
motif mimetics connected by a chemical linker (Fig. 4) 
[119, 120]. The bivalent antagonists have the ability 
to bind simultaneously to XIAP BIR2 and BIR3 domains, 
leading to better activation of caspases [47, 121]. 
Mechanistic aspects of IAP antagonism
Work from several groups established that single-
agent pro-apoptotic activity of Smac-mimicking IAP an-
tagonists results from c-IAP1/2 antagonism and TNFα-
dependent cell death [47, 119, 122–124]. Treatment with 
IAP antagonists causes c-IAP1 and c-IAP2 degradation 
within minutes. For a long time this rapid loss of c-IAP 
proteins was not well understood. However, recent 
biochemical and structural studies have solved this 
mystery and provided a molecular explanation. IAP 
antagonist binding to c-IAP1 cause a conformational 
change that opens the c-IAP1 structure and allows 
c-IAP RING domain dimerization (Fig. 5) [125]. RING 
mediated dimerization activates c-IAP1/2 E3 ligase 
activity, leading to autoubiquitination and subsequent 
proteasomal degradation [125, 126].
Fig. 4. Examples of monovalent (MV1 and GDC-0152) and 
bivalent IAP antagonists (BV6)
A concomitant consequence of heightened ubi-
quitin ligase activity of the c-IAP proteins is ubiquitina-
tion of RIP1, leading to canonical NF-κB activation. Pro-
teasomal degradation of c-IAPs allows for stabilization 
of NIK and stimulation of the noncanonical NF-κB path-
way [47, 120]. The activation of NF-κB as well as MAPK 
pathways induces the transcription and synthesis 
of TNFα, which, in an autocrine or paracrine fashion, 
can subsequently activate TNFR1 signaling [47]. How-
ever, in the absence of c-IAP1 and c-IAP2 the canonical 
NF-κB pathway cannot be activated and RIP1 cannot 
be ubiquitinated. Instead, RIP1 will form the apoptotic 
complex with FADD-caspase-8 to provoke cell death 
[47]. By now, it has been shown in numerous studies 
that single-agent IAP antagonist stimulated cell death 
is absolutely TNFα-dependent and most of the cell 
lines that are sensitive to this treatment constitutively 
secrete elevated levels of TNFα [33, 47, 122].
IAP antagonists predominantly induce apoptotic cell 
death, as is the case of Jurkat cells when treated with 
IAP antagonists in combination with TNFα. However, 
in the absence of FADD or caspase-8, the treatment with 
TNFα and IAP antagonists leads to activation of necrosis 
in Jurkat cells [127]. Similarly, treatment of HT29 cells 
with IAP antagonists and TNFα in the presence of cas-
pase inhibitors strongly stimulates a necrotic response 
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[128]. Therefore, IAP antagonists can cause cell death 
even if the apoptotic pathways are blocked. Although 
many aspects of necroptosis are still poorly defined, 
it seems that the ability of IAP antagonists to stimulate 
necrotic cell death is limited to cells expressing RIP3, 
a critical mediator of this death pathway.
As stated earlier, cells that already secrete TNFα 
or can be induced to produce TNFα upon IAP antago-
nist treatment, can be efficiently killed by IAP antago-
nism [33, 47, 122]. Nevertheless, some resistant cell 
lines can be pushed over the death threshold by the 
addition of TNFα [33, 47, 122, 129]. These resistant 
cell lines might lack the capacity to produce TNFα. 
However, there is another group of resistant cell lines 
that cannot be killed by IAP antagonists even in the 
presence of exogenously added TNFα. The reason 
for this resistance is not clear but it might include in-
creased levels of c-IAP2 and XIAP or low levels of criti-
cal mediators of TNF signaling.
In a few instances it has been reported that 
IAP antagonist treatment will boost c-IAP2 le-
vels in resistant cancer cell lines [130]. c-IAP2 can 
functionally substitute for the absence of degraded 
c-IAP1 and block apoptosis induction by maintain-
ing ubiquitination of RIP1 within the TNFR1 complex 
[130]. Upregulation of c-IAP2 can be a consequence 
of the activation of the NF-κB pathways by IAP an-
tagonists, since c-IAP2 is a NF-κB inducible gene, 
or of c-IAP1 loss, given that c-IAP1 can promote 
ubiquitination of c-IAP2 [130]. It was suggested that 
c-IAP2 up regulation in some resistant cell lines could 
be due to modifications in other pathways that regulate 
c-IAP2 expression such as the phosphoinositide-3 ki-
nase (PI3K) pathway [130].
In general, induction or presence of TNFα is not 
always sufficient for effective induction of cell death 
after IAP antagonist treatment. It has been speculated 
that in those cases antagonism of XIAP is incomplete 
leading to a lack of pro-apoptotic activity of IAP an-
tagonists [121, 129, 131]. In agreement with those re-
ports, a c-IAP-selective antagonist (CS3) can produce 
the same levels of NF-κB signaling pathway activation 
and cause c-IAP1 and c-IAP2 degradation as a pan-IAP 
antagonist (PS1) [132]. However, CS3 does not induce 
cell death nearly as efficiently as PS1 [132]. These 
results reinforce the idea that XIAP needs to be ef-
fectively antagonized to achieve significant apoptosis.
Anti-tumor activity and clinical applications 
of IAP antagonists
IAP antagonists such as BV6, GDC-0152 and 
SM-164 have demonstrated tumor-inhibiting activ-
ity in several in vivo xenograft models [33, 118, 129]. 
Importantly, these compounds did not show any 
significant toxicity or weight loss in mice and could 
produce lasting effects on tumor growth inhibition 
[33, 133]. In addition, IAP antagonists have not shown 
a marked sensitization to apoptosis in normal primary 
cells to date, nor have they affected highly proliferative 
tissues in mice [33, 133].
The IAP antagonist LBW242 was tested in human 
and murine neuroblastoma cells and it sensitized cells 
to apoptosis when it was given in combination with 
vincristine or doxorubicin [134]. It was reported that 
caspase-8 activation might be achieved in a TNFα 
independent manner through the formation of the 
ripoptosome, a complex specific to some cancer 
cell lines [135, 136]. A number of other chemothera-
peutic drugs seem to have a synergistic effect when 
given in combination with Smac mimetics including 
gemcitabine, etoposide, cisplatin, 5-fluorouracil, 
vinorelbine, irinotecan and cytarabine [33]. IAP an-
tagonists have also been reported to enhance not only 
chemotherapy but also radiotherapy effects in pancre-
atic cancer, prostate cancer and glioblastoma [33]. 
In gliobastoma, it was shown that NF-κB activation was 
crucial for sensitization of IAP antagonists to radiation 
[137]. IAP antagonists have also been successfully 
tested in combination with the death receptor ligand 
TRAIL/Apo2L and death receptor agonistic antibodies 
in numerous studies. In most instances, the treatment 
with IAP antagonists was able to render cells sensitive 
to TRAIL-induced cell death [138], and in IAP antago-
nist resistant cells this combination did not rely on TNF 
signaling, but rather on the antagonism of the caspase 
inhibitor XIAP [121].
Based on the positive results from pre-clinical 
studies, several IAP antagonists have entered phase 
I clinical trials [33, 118]. Bivalent IAP antagonists are 
more efficacious in tumor growth inhibition compared 
to monovalent antagonists, probably because of their 
ability to more effectively block XIAP-mediated inhibi-
tion of caspases [33, 121]. The first IAP antagonist 
to enter human clinical trials was compound GDC-
0152, a potent inhibitor of c-IAP1/2, XIAP and ML-IAP 
[133]. Administration of GDC-0152 in mice that had 
been implanted with a xenograft of a sensitive breast 
cancer cell line showed a significant reduction of the 
tumor growth [133]. GDC-0152 showed linear phar-
macokinetics over a wide range of doses in humans 
without any signs of significant toxicity [133]. Simi-
larly, clinical trials with other IAP antagonists, LCL161, 
HGS1029 and TL32711, reported no dose-limiting 
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Fig. 5. IAP antagonists trigger a conformational change in c-IAP1 prompting RING dimerization and activation of E3 ligase activity
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toxicity, target antagonism and dose proportional 
pharmacokinetics [33]. These and other ongoing and 
future clinical trials will examine the safety and the ef-
ficacy of IAP antagonists for the treatment of human 
malignancies in hopes of bringing new anti-tumor 
agents to cancer patients.
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